Immunocore is a pioneering clinical-stage T cell receptor biotechnology company working to develop and commercialise a new generation of transformative medicines to address unmet needs in cancer, infection and autoimmune disease

 

Background

  • A pioneering clinical-stage T cell receptor biotechnology company developing a new generation of medicines
  • Preparing for US/EU approval and launch of first-ever TCR therapy for uveal melanoma, a disease for which there are no treatments
  • Consilium has been an advisor since 2015

 

Strategy

  • Supported Immunocore’s $320 million raise, then Europe’s largest ever private financing, and Nasdaq IPO totalling $312 million
  • Comms activities and profiling around management changes in 2019, including the appointment of Bahija Jallal as CEO
  • Ongoing preparations ahead of potential approval and commercialisation of first TCR therapy, including update to corporate messages and proactive comms strategy ahead of launch

$312 million

Europe’s largest ever private financing, and Nasdaq IPO

 

Outcome

  • Heightened media profile and significant coverage across international business media and trade publications including the Financial Times, The Times, The Telegraph and The Wall Street Journal
  • Immunocore’s reputation protected and strengthened in key media